Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/48958| Title: | Diagnostic, Therapeutic, and Prognostic Implications of Carpal Tunnel Syndrome and Spinal Stenosis in Wild-type ATTR-Cardiomyopathy | Authors: | Debonnaire, Philippe Dujardin, Karl Donal, Erwan Verheyen, Nicolas DUPONT, Matthias Vervloet, Delphine Pouleur, Anne-Catherine TIMMERMANS, Philippe Droogmans, Steven Issa, Victor Sarli Dulgheru, Raluca Jurcut, Ruxandra Regeer, Madelien Bondue, Antoine Christiaen, Emma L'Hoyes, Wouter Wyseure, Nicolas Bezard, Melanie Zach, David Schwegel, Nora Knapen, Robbe Buytaert, Lars de Marneffe, Nils Adam, Robert Marsan, Nina Ajmone Bonte, Francis Vantomme, Nikolaas Buysschaert, Ian Tavernier, Rene Trenson, Sander |
Issue Date: | 2026 | Publisher: | ELSEVIER | Source: | Jacc. Advances, 5 (3) (Art N° 102631) | Abstract: | Background In wild-type transthyretin cardiac amyloidosis (ATTRwt-CM), the prognostic role of carpal tunnel syndrome (CTS) is unclear and that of lumbar spinal stenosis (SS) remains unexplored. Objectives The aim was to examine the diagnostic, therapeutic, and prognostic relevance of bilateral CTS and SS in ATTRwt-CM, in relation to the tafamidis treatment. Methods Clinical characteristics of 1,449 patients with ATTRwt-CM were evaluated in a multicenter cohort. The primary endpoint was all-cause mortality. Cox multivariable regression was used to assess mortality in patients with and without CTS and SS. Results Preceding an ATTRwt-CM diagnosis, CTS and SS were present in 29% and 22% of patients, respectively, without sex-difference. CTS (P < 0.001), but not SS, was more prevalent among younger patients. Tenosynovial red flags and ATTRwt-CM diagnosis occurred approximately 4 years later in females vs males, with similar preceding time, suggesting later female ATTRwt-CM disease onset. Patients with vs without CTS and SS had lower National Amyloidosis Centre disease stage (P <= 0.001), despite similar symptomatic status. During a mean follow-up of 2.3 +/- 1.8 years, 73% (1,052/1,449) of patients were initiated on tafamidis and 28% (406) died. Tafamidis was initiated more in CTS positive vs negative patients (78% vs 71%; P = 0.008), on average 2.3 years earlier (P < 0.001). More SS positive than negative patients received tafamidis (78% vs 71%; P = 0.018), but at similar age (P = 0.394). CTS (HR: 0.70; 95% CI: 0.52-0.95) and SS (HR: 0.68; 95% CI: 0.48-0.97) predicted lower mortality. Conclusions Both CTS and SS not only enable early ATTRwt-CM diagnosis and treatment initiation, but independently relate to improved survival, potentiating a role for opportunistic screening. (c) 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Notes: | Debonnaire, P (corresponding author), Sint Jan Hosp Bruges, Ruddershove 10, B-8000 Brugge, Belgium. philippe.debonnaire@azsintjan.be |
Keywords: | cardiac amyloidosis;carpal tunnel syndrome;mortality;spinal stenosis;tafamidis;transthyretin | Document URI: | http://hdl.handle.net/1942/48958 | ISSN: | 2772-963X | DOI: | 10.1016/j.jacadv.2026.102631 | ISI #: | 001734699100001 | Rights: | 2026 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.